# Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

> **NCT01797120** · PHASE2 · COMPLETED · sponsor: **PrECOG, LLC.** · enrollment: 131 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Everolimus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01797120
- **Lead sponsor:** PrECOG, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-31
- **Primary completion:** 2017-03-22
- **Final completion:** 2017-09-12
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2018-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01797120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01797120, "Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01797120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*